Nanobased drug delivery PowerPoint

							             Targeted drug delivery
              by nanoparticles and
                  theranostics




SRPA Leader: Rafi Korenstein
Tel-Aviv University
E-mail: korens@post.tau.ac.il
               delivery routes




nanocarriers                     targeting
             Strategic Goals


• Develop activity that will lead to the formation
  of long term research collaboration with
  industry (e.g. initiation by STREP and IP in the
  7th Framework Program of EC followed by
  industry supported research)

• Form an expertise reference point for
  industry, research institutes and society
       Scientific General Goals (1)
Development of new multifunctional targeted drug
  delivery systems:

• Develop innovative nanoparticles and nanocapsules as
  drug carrier systems for new drugs

• Examine novel approaches for enhancing the ability to
  pass the cell/tissue barriers (mucosal lining, air-blood
  barrier of the human lung, blood-brain barrier)

• Explore novel targeting strategies (ppreferably
  combined with bioimaging capacity of the targeted
  areas)
       Scientific General Goals (2)
• Investigate ways for enhanced uptake of carriers
  for intracellular targets.

• Development and validation of in-vitro models
  mimicking the in-vivo characteristics of human
  tissues and organs for the examination of drug
  uptake and toxicity aiming to limit in-vivo animal
  testing.

• Theranostics (diagnostics & therapeutics) –
  Integration of fast diagnostic devices and drug
  therapy involving a feedback loop to monitor and
  improve drug efficiency and to minimize side
  effects (individual therapy).
               Specific Goals
• Cancer therapy - formation of integrated
  approach to metastatic cancer therapy through
  combined chemotherapy linked to nanocarriers
  and electrical accelerated uptake of the
  chemotherapy in the primary tumor

• Active drug delivery – MEMS/NEMS devices
  for regulated drug delivery (Microchip-based
  drug delivery consisting of microfluidics
  combined with sensors

• Drug delivery of proteins and peptides

• Toxicology of nanaocarriers
Advantages of nanoparticles as drug carriers

 Large surface-to-volume ratio resulting
  enhanced interaction sites

 Surface functionalization for targeting

 Suitable encapsulation

 Release drugs in controlled manner

 More efficient uptake by cells
          Active drug delivery
  MEMS/NEMS devices for regulated drug delivery
  (Microchip-based drug delivery consisting of
  microfluidics combined with sensors

 MEMS/NMEMS based devices

 Release of drug (alone or associated with a
  nanoparticle carrier)

 Sensing (electrical, optical or chemical) enabling
  closed loop drug delivery
    Drug delivery by implantable nano/micro
          devices (semi implantable)


  Development of 'smart' systems for the release of
  therapeutic agents by devices placed at appropriate
  sites:

 Concentration of therapeutic action exclusively or
  predominantly at a desired target site (targeting)

 Avoidance of barriers to the penetration thereby
  increase the efficacy of the therapeutic action
 Advantages of local drug release strategies
       over systhemic drug therapy

• Lower doses required
• Greater control over toxicity and bioavailability of
  dose
• Extended duration of release
• Possibilities to combine local and systemic drugs
  with different kinetics
• Controlled release directly to site
• Avoidance of systemic drug exposure
General characteristics of the device

Sensors (electrical, electrochemical,
chemical, optical or other detection modes)

Mode of drug release (e.g. feedback)

Power (micro-bateries)

Biocompatibility (through surface
modification)
                   Limitations

• Fully implantable devices are restricted in the
  amount of drug to be released

• The requirement of surgical procedure for
  implantation

• Biofouling/biocompatibility
         Intersection Projects
  During the last annual meeting of N2L in Sitges (Barcellona)
  March 2006, the intersection on implantable drug delivery
  systems was discussed. The need of targeting on specific
  clinically oriented goals was discussed in a forum consisting
  of about 20 participants. In view of this discussion and
  taking into consideration the priorities of research in the
  area of drug delivery in the field of nanomedicine it has
  been decided to concentrate at present on two specific
  clinically oriented intersection topics:

 Diabetes

 Cancer therapy

  More details on these two intersection projects are available
  on the conference website.